Rec'd PCT/PTO 08 MAR 2005

Relevant to claim No.

PCT/GB 03/03951

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 A61K31/551 A61P25/14

C. DOCUMENTS CONSIDERED TO BE RELEVANT

A61P25/16

A61K45/06

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

Citation of document, with indication, where appropriate, of the relevant passages

EPO-Internal, WPI Data, PAJ, EMBASE, BIOSIS, MEDLINE, CHEM ABS Data, SCISEARCH

X Y	US 6 200 970 B1 (ANDR AACUTE SI AL) 13 March 2001 (2001-03-13) column 1, line 16 - line 55	1,2,5,8, 9,12,25 1,2,5, 8-11, 14-20		
	column 2, line 29 - line 40 column 2, line 64 -column 3, line examples 3,6	e 15 _.		
Y	EP 0 900 568 A (PFIZER PROD INC) 10 March 1999 (1999-03-10)		1,2,5, 8-11, 14-20	
	page 2, line 5 - line 33 page 10, line 50 -page 11, line	13		
		-/		
X Furt	her documents are listed in the continuation of box C.	X Patent family members are listed	l in annex.	
"A" documo consid "E" earlier	ategories of cited documents : ent defining the general state of the art which is not dered to be of particular relevance document but published on or after the international	"T" later document published after the Into or priority date and not in conflict with cited to understand the principle or the invention "X" document of particular relevance; the	the application but learning the	
which citatio	ent which may throw doubts on priority claim(s) or Is cited to establish the publication date of another In or other special reason (as specified)	cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the		
other	ent referring to an oral disclosure, use, exhibition or means ent published prior to the international filing date but han the priority date claimed	document is combined with one or m ments, such combination being obvior in the art. "&" document member of the same patent	ous to a person skilled	
Date of the	actual completion of the international search	Date of mailing of the international se	earch report	
1	5 January 2004	13/02/2004		
Name and	mailing address of the ISA European Patent Office, P.B. 5818 Patentiaan 2 NL – 2280 HV Rijswijk Tel. (+31–70) 340–2040, Tx. 31 651 epo nl, Fax: (+31–70) 340–3016	Authorized officer Cielen, E		



Int Application No
PCT/GB 03/03951

	ation) DOCUMENTS CONSIDERED TO BE RELEVANT	
Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Υ ·	KONITSIOTIS S ET AL: "AMPA receptor blockade improves levodopa-induced dyskinesia in MPTP monkeys" NEUROLOGY, vol. 54, no. 8, 25 April 2000 (2000-04-25), pages 1589-1595, XP008026187 ISSN: 0028-3878 abstract page 1590, column 1, paragraph 1 page 1592, column 2, paragraph 2	1,2,5, 8-11, 14-19
X	page 1594, column 1, paragraph 2 REVUTSKY E L ET AL: "Prophylaxis of meteopathological reactions in patients with ischemic heart disease and neurocirculatory dystonia" VRACHEBNOE DELO 1988 RUSSIA, no. 2, 1988, pages 7-10, XP008026189 ISSN: 0049-6804	1-8
A	abstract TARNAWA I. ET AL: "2,3-Benzodiazepine AMPA antagonists." RESTORATIVE NEUROLOGY AND NEUROSCIENCE, (1998) 13/1-2 (41-57)., XP008026184 abstract page 42, column 1, paragraph 3	1-7
A .	SÓLYOM S ET AL: "Non-competitive AMPA antagonists of 2,3-benzodiazepine type" CURRENT PHARMACEUTICAL DESIGN 2002 NETHERLANDS, vol. 8, no. 10, 2002, pages 913-939, XP008026188 ISSN: 1381-6128 figure CHART2 page 921, column 1, paragraph 1	1-7
A	US 4 322 346 A (KOROSI JENO ET AL) 30 March 1982 (1982-03-30) column 1, line 6 - line 43 column 4, line 3 - line 7 examples	1-5,8,25
		·



lı		pplication No
PC	T/GB	03/03951

C.(Continu	C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT							
Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.						
P,X	WO 02 088096 A (LAGOUGE YAN; NEURO3D (FR); LUGNIER CLAIRE (FR); UNIV PASTEUR (FR);) 7 November 2002 (2002-11-07) page 2, line 1 -page 3, line 27 page 8, line 29 -page 9, line 14 page 10, line 9 - line 12 page 10, line 18 page 11, line 5 page 13, line 14 - line 28 page 14, line 14 - line 17	1-9,13, 25						
P,X	BROTCHIE J M ET AL: "THE EFFECTS OF TOFISOPAM ON THE ACTIONS INDUCED BY L - DOPA ADMINISTRATION IN THE MPTP - LESIONED NON - HUMAN PRIMATE MODEL OF PARKINSON'S DISEASE." SOCIETY FOR NEUROSCIENCE ABSTRACT VIEWER AND ITINERARY PLANNER, vol. 2002, 2002, page Abstract No. 165.18 XP008026196 32nd Annual Meeting of the Society for Neuroscience; Orlando, Florida, USA; November 02-07, 2002 the whole document	1-7, 14-19						
P,X	DATABASE WPI Week 200317, 27 December 2002 (2002-12-27) Derwent Publications Ltd., London, GB; AN 2003-173629 XP002266976 BELOBORODOVA ET AL.: "Method of treatment of hypertension-hyperkinetic form of dyskinesia of biliferous ways in young persons" & RU 2 195 284 C (BELOBORODOVA ET AL.), 27 December 2002 (2002-12-27) abstract	1,2,4-6, 8,25						
P,X	WO 02 094189 A (LEVENTER STEVEN M; KUCHARIK ROBERT (US); VELA PHARMACEUTICALS INC) 28 November 2002 (2002-11-28) page 5, line 8 - line 14 page 6, line 23 -page 7, line 11 page 15, line 12 - line 14 page 16, line 9 - line 19 page 17, line 14 - line 18	1-9,12, 13,25						
А	BEERS M. AND BERKOW R.: "The Merck Manual of Diagnosis and Therapy, 17th Edition" 1999 , MERCK RESEARCH LABORATORIES , WHITEHOUSE STATION, N.J. XP002267011 page 1462 -page 1473							

	nt document search report		Publication date		Patent family member(s)	Publication date
	200970	B1	13-03-2001	DE	19604920 A1	07-08-1997
				ΑT	216373 T	15-05-2002
				AU	2285997 A	22-08-1997
				CA	2244777 A1	07-08-1997
				WO	9728135 A1	07-08-1997
				DE	59707062 D1	23-05-2002
				DK	888313 T3	15-07-2002
				EP	0888313 A1	07-01-1999
				ES.	2175386 T3	16-11-2002
				HŬ	9901473 A2	28-09-1999
				JP	2000505793 T	16-05-2000
				PT	888313 T	30-09-2002
				ZA	9700850 A	04-08-1997
FP 0	900568	 А	10-03-1999	AU	736254 B2	26-07-2001
L. U	20000	,,	10 00 1999	AU	8312098 A	18-03-1999
				CA	2246839 A1	05-03-1999
				EP	0900568 A2	10-03-1999
				ĤÜ	9802021 A2	28-05-1999
				JP	11158072 A	15-06-1999
				JP	2001316267 A	13-11-2001
				NZ	331741 A	25-08-2000
				ÜS	6136812 A	24-10-2000
				ZA	9808139 A	22-03-2000
	 1322346	Α	30-03-1982	HU	179018 B	28-08-1982
03 4	1366340	Λ	20 -03-1305	AT	373589 B	10-02-1984
			•	AT	647279 A	15-06-1983
				AU	532079 B2	15-00-1983
				BE	879404 A1	15-04-1980
				BG	60270 B2	31-03-1994
				CA	1125749 A1	15-06-1982
				CH	643835 A5	29-06-1984
				CS	236456 B2	15-05-1985
				DD	146596 A5	18-02-1981
•				DE	2940483 A1	30-04-1980
					440179 A ,	
•				DK ES	485163 A1	16-06-1980
				FI	793209 A ,	
				FR	2439189 A1	16-05-1980
				GB	2034706 A ,	
				GR	74034 A1	06-06-1984
				IT	1220947 B	21-06-1990
				JP	1505220 C	13-07-1989
				JP	55092377 A	12-07-1989
				JP	63050354 B	07-10-1988
				NL	7907692 A ,	,
				NO DI	793349 A ,	
				PL	219034 A1	01-12-1980
				SE	439919 B	08-07-1985
				SE	7908481 A	20-04-1980
				SU YU	1402258 A3 241079 A1	07-06-1988 29-02-1984
			07 11 0000			
MO (02088096	Α	07-11-2002	FR	2824065 A1	31-10-2002
_				WO	02088096 A1	07-11-2002
						·



Int i	pplication No	
PCT/GB	03/03951	

Patent document cited in search report	Publication date		Patent family member(s)	Publication date
W <u>O</u> 02094189 A	28-11-2002	US AU BR CA EP GB JP NZ WO	2003055048 A1 3702802 A 0201862 A 2381637 A1 1262184 A1 2377636 A 2003012518 A 518675 A 02094189 A2	20-03-2003 21-11-2002 25-03-2003 18-11-2002 04-12-2002 22-01-2003 15-01-2003 25-07-2003 28-11-2002